| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on November 29, 2004
Accepted on April 1, 2005
Endocrine Unit, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Rd, London W12 ONN, UK
* To whom correspondence should be addressed. E-mail: s.bloom{at}imperial.ac.uk.
Relaxin-3 (INSL-7) is a recently discovered member of the insulin superfamily. Relaxin-3 mRNA is expressed in the nucleus incertus of the brain stem which has projections to the hypothalamus. Relaxin-3 binds with high affinity to the LGR7 receptor and to the previously orphan G protein-coupled receptor GPCR135. GPCR135 mRNA is expressed predominantly in the CNS, particularly in the paraventricular nucleus (PVN). The presence of relaxin-3 and these receptors in the PVN led us to investigate the effect of central administration of relaxin-3 on food intake in male Wistar rats. The receptor involved in mediating these effects was also investigated. Intracerebroventricular (ICV) injections of human relaxin-3 (H3) to satiated rats significantly increased food intake 1 h post-administration in the early light phase [0.96 ± 0.16 g (vehicle) vs. 1.81 ± 0.21 g (180 pmol H3), P < 0.05] and the early dark phase [2.95 ± 0.45 g (vehicle) vs. 4.39 ± 0.39 g (180 pmol H3), P < 0.05]. IntraPVN H3 administration significantly increased 1 h food intake in satiated rats in the early light phase [0.34 ± 0.16 g (vehicle) vs. 1.23 ± 0.30 g (18 pmol H3), P < 0.05] and the early dark phase [4.43 ± 0.32 g (vehicle) vs. 6.57 ± 0.42 g (18 pmol H3), P < 0.05]. Feeding behavior increased following iPVN H3. Equimolar doses of human relaxin-2, which binds the LGR7 receptor but not GPCR135, did not increase feeding. Hypothalamic NPY, POMC or AgRP mRNA expression did not change following acute ICV H3. These results suggest a novel role for relaxin-3 in appetite regulation.
This article has been cited by other articles:
 |
|
 |
|
  C. Kuei, S. Sutton, P. Bonaventure, C. Pudiak, J. Shelton, J. Zhu, D. Nepomuceno, J. Wu, J. Chen, F. Kamme, et al. R3(B{Delta}23 27)R/I5 Chimeric Peptide, a Selective Antagonist for GPCR135 and GPCR142 over Relaxin Receptor LGR7: IN VITRO AND IN VIVO CHARACTERIZATION J. Biol. Chem., August 31, 2007; 282(35): 25425 - 25435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. T. van der Westhuizen, T. D. Werry, P. M. Sexton, and R. J. Summers The Relaxin Family Peptide Receptor 3 Activates Extracellular Signal-Regulated Kinase 1/2 through a Protein Kinase C-Dependent Mechanism Mol. Pharmacol., June 1, 2007; 71(6): 1618 - 1629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. M. McGowan, S. A. Stanley, N. E. White, A. Spangeus, M. Patterson, E. L. Thompson, K. L. Smith, J. Donovan, J. V. Gardiner, M. A. Ghatei, et al. Hypothalamic mapping of orexigenic action and Fos-like immunoreactivity following relaxin-3 administration in male Wistar rats Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E913 - E919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Smith, M. Patterson, W. S. Dhillo, S. R. Patel, N. M. Semjonous, J. V. Gardiner, M. A. Ghatei, and S. R. Bloom Neuropeptide S Stimulates the Hypothalamo-Pituitary-Adrenal Axis and Inhibits Food Intake Endocrinology, July 1, 2006; 147(7): 3510 - 3518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Rosengren, F. Lin, R. A. D. Bathgate, G. W. Tregear, N. L. Daly, J. D. Wade, and D. J. Craik Solution Structure and Novel Insights into the Determinants of the Receptor Specificity of Human Relaxin-3 J. Biol. Chem., March 3, 2006; 281(9): 5845 - 5851. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
